Butein ameliorates chronic stress induced atherosclerosis via targeting anti-inflammatory, anti-fibrotic and BDNF

Mujeeba Rehman1, Rishabh Chaudhary1, Sonu Rajput1

  • 1Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow, Uttar Pradesh 226025, India.

Physiology & Behavior
|April 26, 2023
PubMed

Insights

Chronic stress promotes atherosclerosis, a key factor in cardiovascular diseases (CVDs). This study validated a chronic unpredictable stress (CUS) mouse model and found the polyphenol Butein protects against stress-induced atherosclerosis via anti-inflammatory and antifibrotic actions.

Area of Science:

  • Cardiovascular Science
  • Stress Physiology
  • Pharmacology

Background:

  • Chronic stress is a significant risk factor for cardiovascular diseases (CVDs).
  • Stress elevates pro-inflammatory cytokines, increasing susceptibility to atherosclerosis.
  • A validated mouse model is crucial for studying stress-induced atherosclerosis.

Purpose of the Study:

  • To validate a chronic unpredictable stress (CUS) mouse model for atherosclerosis research.
  • To assess the protective effects of the polyphenol Butein against CUS-induced atherosclerosis.
  • To elucidate the mechanisms underlying Butein's protective actions.

Main Methods:

  • Mice were subjected to a 10-week chronic unpredictable stress (CUS) protocol.
  • Stress response was confirmed by behavioral tests and serum corticosterone levels.
  • Atherosclerosis was evaluated via lipid indices, plaque deposition, and fibrosis in the thoracic aorta.
  • Butein (20 mg/kg) was administered for the final 4 weeks of the CUS protocol.

Main Results:

  • CUS induced depressive-like behaviors and elevated corticosterone levels.
  • Butein treatment reduced peripheral IL-1β and increased BDNF levels.
  • Histological analysis showed decreased macrophage expression and fibrosis in the thoracic aorta of Butein-treated mice.
  • Butein administration lowered lipid indices in CUS mice.

Conclusions:

  • Ten weeks of CUS effectively induces atherosclerosis features in mice.
  • Butein demonstrates protective effects against chronic stress-induced atherosclerosis.
  • Butein's mechanisms include anti-inflammatory, antifibrotic, and anti-adipogenic actions.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
494
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
58
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474